Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of NNC0165-1562 and Semaglutide in Subjects With Overweight or Obesity

NCT03574584 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03574584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03574584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of NNC0165-1562 and Semaglutide in Subjects With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2018
Completion date
July 27, 2019
Enrollment
37 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metabolism and nutrition disorders, overweight or obesity